Scott Myers joined Viridian as President and Chief Executive Officer and a member of the board of directors in February 2023. He has more than 30 years of biopharmaceutical and medical technology experience, and has held global executive leadership and director roles at numerous commercial- and development-stage biopharmaceutical companies.

Previously, Scott served as the CEO and Director of AMAG Pharmaceuticals, where he led its turnaround and strategic sale to Covis Pharma. Prior to AMAG, he served as CEO and Chairman of the Board of Rainier Therapeutics, a late-stage oncology company. Previous roles include serving as CEO, President and Director of Cascadian Therapeutics until its acquisition by Seagen, and as CEO of Aerocrine AB, a medical technology company. While CEO of these companies, Scott and his teams transformed the companies to focus on creating and advancing innovative products to deliver significant shareholder value.

Scott began his career in management consulting and then moved into the pharmaceutical industry through senior commercial leadership roles in the United States and globally at Johnson & Johnson, DOV Pharmaceuticals, and UCB.

He holds a bachelor’s degree in biology from Northwestern University and a master’s degree in business administration from the University of Chicago Booth School of Business.

Scott serves on the board of directors at Dynavax Technologies, Harpoon Therapeutics, Ironshore Therapeutics, Selecta Biosciences, and Sensorion. He was previously an Independent Director at Trillium Therapeutics until its acquisition by Pfizer.